Novaliq establishes U.S. subsidiary

Heidelberg, Germany-based Novaliq GmbH announced that it will establish a subsidiary in Cambridge, Mass., which will be headed by the company’s founder and chief information officer, Bernhard Günther.

The company, which specializes in a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for the eye, said in a press release that it aims to strengthen its presence in the growing U.S. eye care market.

Novaliq said it is pursuing two late-stage clinical trials in the U.S.

ESSENCE is a phase 2b/3 randomized, double-masked, vehicle-controlled multicenter trial designed to evaluate the safety, efficacy and tolerability of topical CyclASol for treating dry eye disease. SEECASE is a phase 2, multicenter, randomized, double-masked, saline-controlled study to evaluate NOV03 at two different dosing regimens for treating the signs and symptoms of evaporative dry eye disease.

“In the U.S., more than 16 million patients are diagnosed with dry eye disease; however, only approximately 10% are being treated,” Novaliq CEO Christian Roesky, PhD, said in the release. “This significant gap is a clear indication that new dry eye disease therapies are needed. A strong presence in the United States will assist us to better serve this vital pharma market.”

Heidelberg, Germany-based Novaliq GmbH announced that it will establish a subsidiary in Cambridge, Mass., which will be headed by the company’s founder and chief information officer, Bernhard Günther.

The company, which specializes in a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for the eye, said in a press release that it aims to strengthen its presence in the growing U.S. eye care market.

Novaliq said it is pursuing two late-stage clinical trials in the U.S.

ESSENCE is a phase 2b/3 randomized, double-masked, vehicle-controlled multicenter trial designed to evaluate the safety, efficacy and tolerability of topical CyclASol for treating dry eye disease. SEECASE is a phase 2, multicenter, randomized, double-masked, saline-controlled study to evaluate NOV03 at two different dosing regimens for treating the signs and symptoms of evaporative dry eye disease.

“In the U.S., more than 16 million patients are diagnosed with dry eye disease; however, only approximately 10% are being treated,” Novaliq CEO Christian Roesky, PhD, said in the release. “This significant gap is a clear indication that new dry eye disease therapies are needed. A strong presence in the United States will assist us to better serve this vital pharma market.”